Literature DB >> 22723572

The role of mitochondria in axonal degeneration and tissue repair in MS.

J van Horssen1, M E Witte, O Ciccarelli.   

Abstract

Axonal injury is a key feature of multiple sclerosis (MS) pathology and is currently seen as the main correlate for permanent clinical disability. Although little is known about the pathogenetic mechanisms that drive axonal damage and loss, there is accumulating evidence highlighting the central role of mitochondrial dysfunction in axonal degeneration and associated neurodegeneration. The aim of this topical review is to provide a concise overview on the involvement of mitochondrial dysfunction in axonal damage and destruction in MS. Hereto, we will discuss putative pathological mechanisms leading to mitochondrial dysfunction and recent imaging studies performed in vivo in patients with MS. Moreover, we will focus on molecular mechanisms and novel imaging studies that address the role of mitochondrial metabolism in tissue repair. Finally, we will briefly review therapeutic strategies aimed at improving mitochondrial metabolism and function under neuroinflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22723572     DOI: 10.1177/1352458512452924

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  23 in total

1.  NADH-dehydrogenase type-2 suppresses irreversible visual loss and neurodegeneration in the EAE animal model of MS.

Authors:  Venu Talla; Hong Yu; Tsung-Han Chou; Vittorio Porciatti; Vince Chiodo; Sanford L Boye; William W Hauswirth; Alfred S Lewin; John Guy
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

Review 2.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

Review 3.  The role of glutamate and its receptors in multiple sclerosis.

Authors:  Ivana R Stojanovic; Milos Kostic; Srdjan Ljubisavljevic
Journal:  J Neural Transm (Vienna)       Date:  2014-03-15       Impact factor: 3.575

Review 4.  SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.

Authors:  Vamshi K C Nimmagadda; Tapas K Makar; Krish Chandrasekaran; Avinash Rao Sagi; Jayanta Ray; James W Russell; Christopher T Bever
Journal:  J Neuroimmunol       Date:  2016-07-17       Impact factor: 3.478

5.  Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.

Authors:  Joachim Havla; T Kümpfel; R Schinner; M Spadaro; E Schuh; E Meinl; R Hohlfeld; O Outteryck
Journal:  J Neurol       Date:  2016-11-14       Impact factor: 4.849

Review 6.  Demyelination as a rational therapeutic target for ischemic or traumatic brain injury.

Authors:  Hong Shi; Xiaoming Hu; Rehana K Leak; Yejie Shi; Chengrui An; Jun Suenaga; Jun Chen; Yanqin Gao
Journal:  Exp Neurol       Date:  2015-03-24       Impact factor: 5.330

7.  Complex I subunit gene therapy with NDUFA6 ameliorates neurodegeneration in EAE.

Authors:  Venu Talla; Rajeshwari Koilkonda; Vittorio Porciatti; Vince Chiodo; Sanford L Boye; William W Hauswirth; John Guy
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-22       Impact factor: 4.799

8.  Stressed cybrids model demyelinated axons in multiple sclerosis.

Authors:  Laura Llobet; Aurora Gómez-Durán; Ruth Iceta; Eldris Iglesias; Julio Montoya; Jesús Martín-Martínez; José Ramón Ara; Eduardo Ruiz-Pesini
Journal:  Metab Brain Dis       Date:  2013-04-24       Impact factor: 3.584

9.  Mitochondrial STAT3 is negatively regulated by SOCS3 and upregulated after spinal cord injury.

Authors:  Keun Woo Park; Ching-Yi Lin; Etty N Benveniste; Yu-Shang Lee
Journal:  Exp Neurol       Date:  2016-08-05       Impact factor: 5.330

Review 10.  Microglial Phenotypes and Functions in Multiple Sclerosis.

Authors:  Elaine O'Loughlin; Charlotte Madore; Hans Lassmann; Oleg Butovsky
Journal:  Cold Spring Harb Perspect Med       Date:  2018-02-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.